PSP001 - A First-in-disease human PEGIFN-λ Chimera
| Feb. 03, 2021, FDA approved IND filing and Sigle Ascending Dose trial may Proceed |
| Date:2023-04-06 15:16:49 | Visits： |
| Prev:Prosit Sole had initiated the first-in-human (“FIH”) Phase I clinical trial of PSP001 in US Next:Prosit Sole innitiated a First-in-humans study of the safety, tolerability, and pharmacokinetics of PSP001, a new type of immunomodulator form family Interfon Lambda |
